Background: Pachyderma is defined as severely thickened skin with deep folds and is occasionally observed with primary cutaneous NK and T-cell lymphoma (pCNKTCL), primary cutaneous B-cell lymphoma (pCBCL), and leukemia cutis (LC). Aim: To describe the clinical, histological, and therapeutic particularities of a series of pCNKTCL, pCBCL, and LC patients with pachyderma. Results: In a series of pCNKTCL (n = 70), pCBCL (n = 12), and LC (n = 2) patients followed up during 9 years, 6 cases of pachyderma were observed. Pachyderma occurred on the arms (n = 2), thighs (n = 1), forehead (n = 1), and face (n = 2). The mean age of the patients was 69 years (51-82). The stages were erythrodermic (T4) mycosis fungoides (MF) (n = 1), folliculotropic MF (FMF) (n = 2), classic (T2) MF (n = 2), and chronic myeloid leukemia (n = 1). The erythrodermic MF patient with acute pachyderma on the right arm responded rapidly to oral steroids. The other cases were indolent, appeared progressively, and were highly treatment resistant. Histology revealed dense dermal neoplastic infiltration.
Introduction
Pachyderma is defined as substantially thickened skin with deep folds, as observed in pachyderm animals such as elephants, rhinoceros, and hippopotami. Pachyderma in humans may be observed in several medical conditions -among others, during chronic severe lymphatic insufficiency with lymphedema [1] , pachydermoperiostosis (Touraine-Solente-Golé syndrome) [2] , keratitis-ichthyosis-deafness syndrome [3] , congenital or secondary cutis verticis gyrata [4, 5] , crusted scabies [6] , severely infiltrated scleromyxedema [7] , especially of the face, and lepromatous leprosy, presenting as leonine facies. White sponge nevus is considered a manifestation of pachyderma of the intraoral mucosa.
Mycosis fungoides (MF) is the most frequently encountered manifestation of primary cutaneous NK and T-cell lymphoma (pCNKTCL). Leukemia cutis (LC) is a nonspecific term used for cutaneous manifestations of any type of leukemia. Pachyderma occurring in patients with pCNKTCL [8] and LC [9, 10] has exceptionally been reported. Pachyderma in pCNKTCL patients classically presents as leonine facies and seems restricted to patients with facial folliculotropic MF (FMF) [11] . Leonine facies has also been described in a patient suffering from chronic primary cutaneous B-cell lymphoma (pCBCL) [12] .
The mechanisms and clinical patterns of pachyderma during pCNKTCL and LC are not well elucidated. The aim of this study was to describe the clinical particularities as well as the histological and therapeutic features in a series of pCNKTCL, pCBCL, and LC patients presenting with pachyderma.
Subjects and Methods
The study was performed in accordance with the Declaration of Helsinki (version 2013). The institutional ethics committee approved the design of the study. The patients were informed about the procedures and were invited to fill in a medical questionnaire. All the patients signed the informed consent forms.
A cohort of 84 patients with pCNKTCL (n = 70), pCBCL (n = 12), or LC (n = 2) were included and prospectively followed up during 9 years. In this patient series, the number of patients with pachyderma was assessed. Pachyderma was defined as the presence of thick continuous and concatenated skin folds with prominent convexities and furrowed creases. Age, gender, the anatomical site, the extension and duration of the pachydermic lesions, the underlying disease stage, the pachydermic disease course, and the treatments were recorded for all the cases with pachyderma. A skin biopsy was performed on all pachyderma patients under local anesthesia for histological and immunohistological assessments as well as for PCR to search for monoclonal TCR rearrangement.
Results
Among the 84 patients, 6 fulfilled the above-mentioned criteria for pachyderma during the observation period. The anatomical sites were the arms (n = 2), buttocks (n = 1), forehead (n = 1), and face (n = 2). The mean age of the pachyderma patients was 69 years (min. 51, max. 82). The disease stages at the moment of diagnosis of pachyderma were erythrodermic (T4 stage) MF (n = 1), FMF (n = 2), classic type (T1/2 stage) MF (n = 2), and chronic myeloid leukemia (n = 1). All the MF and FMF patients had a long disease history of pCNKTCL. The extension of the pachyderma of the face and forehead corresponded precisely to the skin area involved in FMF and LC. In contrast, the pachyderma on the extremities only involved part of the total cutaneous extension seen in MF. The pachydermic infiltration of the arms appeared quickly and rapidly responded to oral steroids (Fig. 1) . In contrast, the lesions of the buttocks and the face (Fig. 2) were indolent, appeared progressively, and were highly treatment resistant. The histological examination (Fig. 1, 2 ) of the pachydermic lesions revealed a dense inflammatory and neoplastic infiltrate of the entire dermis with extension to the epidermis and sometimes the hypodermis, but this was otherwise not different from common MF, FMF, and myeloid LC (MLC). The immunohistological profile revealed a dense CD3+, CD4+, CD45R0+, and CD8-infiltrate (Fig. 2) . In all the MF and FMF cases, TCR monoclonality was observed by PCR. This monoclonality was identical to that previously evidenced during the initial workup at diagnosis. In the MLC patient, a dense myeloid infiltrate of the dermis was noted (Fig. 2) . The individual patient data are presented in Table 1 .
The rapid appearance of the pachyderma on the arms (Fig. 1) encouraged the use of systemic oral steroids (methylprednisolone, 125 mg progressively tapered over 2 weeks) and was followed by total regression of the pachydermic aspect (Fig. 1) .
Discussion
Besides classic MF, an important array of atypical MF presentations are encountered, including FMF and syringotropic, verrucous, bullous, vesicular, pustular, granulomatous, alopecic, palmoplantar, unilesional, "tumeur d'emblée"-type, poikilodermic, hypopigmented, hyperpigmented, interstitial, papillomatous, ichthyosiform, mucosal, and pigmented purpuric MF [8, 13, 14] . Transitions from one form to another and coexistence of different forms may be observed. Hence, it is not without reason that MF is often called the great mimicker [8, 13, 14] .
A slow-appearing and chronic form of pachyderma (leonine facies) may be encountered in patients suffering from FMF of the face [11] . It appears as hypertrophy and progressive folding of the facial skin, in particular the forehead. FMF-associated leonine facies is observed in stage IV cutaneous T-cell lymphoma and is often accompanied by some degree of blood involvement. Treatment with local electron beam therapy was recommended [11] .
Although the clinical picture of pachyderma is relatively unequivocal, there is no clear histological definition of pachyderma, as the thickening may have various origins. Tumoral infiltration of neoplastic lymphocytes seems the main reason for pachyderma in FMF [11] and MF, tumoral infiltration of leukemic cells in LC [15] , granulomatous infiltration in the case of leprosy, lymphatic and edematous stowage in patients with lymphatic insufficiency [1] or scleromyxedema [7] , and dense lymphocytic infiltration in the case of prurigo and Norwegian scabies [6] . Granulomatous slack skin may also present a pachydermic aspect, particularly in the skin folds. The folds are caused by a granulomatous infiltration of the dermis by atypical lymphocytes. The folds are even more accentuated due to enzymatic degradation of the elastic fibers, enzymes released by tumoral cells [12, 13] . The two cases of pachyderma affecting the face are similar to the description of FMF-associated leonine facies [11] .
In conclusion, chronic and transitory forms of pachyderma on the extremities may be encountered in patients with long-standing MF and should be recognized as one of the manifestations of MF. Oral steroids seem to represent a beneficial therapeutic option in rapidly appearing pachyderma. Chronic pachyderma on the face is associated with facial involvement of FMF.
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